Pharmacokinetics and pharmacodynamics of azoles

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 327-353

  Mouton, Johan W ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872862626     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (111)

1. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31(1): 327-332.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29(2):239-244.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3):309-317.
4. Woolley DW. Some biological effects produced by benzimidazole and their reversal by purines. J Biological Chem 1944; 152:225-232.
5. Jerchel D, Fischer H, Kracht M. Zur Darstellung der Benzimidazole. Liebigs Annalen der Chemie 1952; 575:162-173.
6. Godefroi EF, Heeres J, Van Cutsem J, Janssen PA. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 1969; 12(5):784-791.
7. Heeres J, Backx LJ, Mostmans JH, Van Cutsem J. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum anti-fungal agent. J Med Chem 1979; 22(8):1003-1005.
8. Heeres J, Hendrickx R, Van Cutsem J. Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal. J Med Chem 1983; 26(4):611-613.
9. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(1): 279-285.
10. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacoki-netic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39(6):877-916.
11. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 2001; 27(1):115-121.
12. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(suppl 3):S318-S326.
13. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos 1991; 19(4):764-767.
14. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32(9):1310-1313.
15. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46(2):147-150.
16. Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res 1994; 14(3):87-93.
17. Zhao Q, Zhou H, Pesco-Koplowitz L. Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. J Clin Pharmacol 2001; 41(12):1319-1328.
18. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42(7):1862-1865.
19. Zhou H, Goldman M, Wu J, et al. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998; 38(7):593-602.
20. Arredondo G, Martinez-Jorda R, Calvo R, Aguirre C, Suarez E. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994; 32(7):361-364.
21. Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacoki-netics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006; 50(12):4096-4102.
22. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61(suppl 1):27-37.
23. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45(7):649-663.
24. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47(9):2788-2795.
25. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(1): 286-293.
26. Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ. Discovery of fluconazole, a novel antifungal agent. Rev Infect Dis 1990; 12 (suppl 3):S267-S71.
27. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157(1):178-180.
28. Sasongko L, Williams KM, Day RO, McLachlan AJ. Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Br J Clin Pharmacol 2003; 56(5):551-561.
29. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995; 36(2):395-401.
30. Arredondo G, Calvo R, Marcos F, Martinez-Jorda R, Suarez E. Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther 1995; 33(8):449-452.
31. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13(4):325-329.
32. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997; 33(1):52-77.
33. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37(4):778-784.
34. Poirier JM, Berlioz F, Isnard F, Cheymol G. Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie 1996; 51(2):163-167.
35. Poirier JM, Hardy S, Isnard F, Tilleul P, Weissenburger J, Cheymol G. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther Drug Monit 1997; 19(5):525-529.
36. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavail-ability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37(6):535-540.
37. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997; 52(3):235-237.
38. Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41(11):2554-2558.
39. Boogaerts MA, Maertens J, Van Der Geest R, et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itracona-zole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001; 45(3):981-985.
40. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmaco-kinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998; 18(2):295-301.
41. Schmitt HJ, Edwards F, Andrade J, Niki Y, Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy 1992; 38(2):118-126.
42. de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42(2):404-408.
43. Mattiuzzi GN, Kantarjian H, O'Brien S, et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100(3): 568-573.
44. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21(24):4615-4626.
45. Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacoki-netics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48(8):3151-3153.
46. Arredondo G, Suarez E, Calvo R, Vazquez JA, Garcia-Sanchez J, Martinez-Jorda R. Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J Antimicrob Chemother 1999; 43(2):305-307.
47. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35(6):461-473.
48. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64(18):1997-2020.
49. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42(4):395-402.
50. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56(suppl 1): 17-23.
51. Hoffman A, Danenberg HD, Katzhendler I, Shuval R, Gilhar D, Friedman M. Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form [In Process Citation]. J Controlled Release 1998; 54(1): 29-37.
52. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56(suppl 1): 10-16.
53. Mar PIL. Label: voriconazole for injection, tablets, oral suspension. In: LAB-0271-12; 2005.
54. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26(12):1730-1744.
55. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50(4):1570-1572.
56. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45(2):185-192.
57. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57(2):218-222.
58. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007. In press.
59. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immu-nologic strategies. Antimicrob Agents Chemother 1996; 40(2):279-291.
60. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A2. Wayne: National Committee for Clinical Laboratory Standards; 2002.
61. Rodriguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect 2003; 9:I-VIII.
62. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45(1):109-111.
63. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43(8):3884-3889.
64. Mouton JW, Voss A, van Elzakker EPM, et al. Linezolid susceptibility of glycopeptide-intermediately susceptible Staphylococcus aureus (GISA)-the Dutch experience. In: ECC-MID; 2003; Glasgow; 2003.
65. Ribeiro da Matta VL, de Souza Carvalho Melhem M, Colombo AL, et al. Susceptibility profile to antifungal drugs of Pichia anomala isolated from patients presenting nosocomial fungemia 10.1128/AAC.01038-06. Antimicrob Agents Chemother 2007;AAC.01038-06.
66. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995; 39(9):2051-2060.
67. Mouton JW, Vinks AA. PK-PD modelling of antibiotics in vitro and in vivo using bacterial growth and kill kinetics: the MIC versus stationary concentrations. Clinical Pharmacoki-netics 2005. In press.
68. NCCLS. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline-Second Edition. NCCLS document M23-A2. Wayne: NCCLS; 2001.
69. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother 1996; 38(4):561-578.
70. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14(4):643-658, table of contents.
71. Altman FP. Tetrazolium salts and formazans. Prog Histochem Cytochem 1976; 9(3):1-56.
72. Meletiadis J, Verweij PE, TeDorsthorst DT, Meis JF, Mouton JW. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol 2005; 43(2):133-152.
73. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39(9): 3402-3408.
74. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly PJ, Verweij PE. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis 2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2h- tetrazolium-hydroxide, for antifungal susceptibility testing of aspergillus species. J Clin Microbiol 20011; 39(12):4256-4263.
75. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Verweij PE. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40(8):2876-2885.
76. Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38(8):2949-2954.
77. Craig WA, Gudmundsson S. Post-antibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th ed. Baltimore: Williams and Wilkins, 1996:296-329.
78. den Hollander JG, Fuursted K, Verbrugh HA, Mouton JW. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 1998; 42(4):749-754.
79. den Hollander JG, Mouton JW, van Goor MP, Vleggaar FP, Verbrugh HA. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1996; 40(3):784-786.
80. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 20000; 44(4):1108-1111.
81. Anil S, Ellepola AN, Samaranayake LP. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease. J Oral Pathol Med 2001; 30(8):481-488.
82. Garcia MT, Llorente MT, Minguez F, Prieto J. Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations of 4 antifungal agents on previously treated Candida spp. Scand J Infect Dis 2000; 32(6):669-673.
83. Garcia MT, Llorente MT, Minguez F, Prieto J. Influence of temperature and concentration on the postantifungal effect and the effects of sub-MIC concentrations of four antifungal agents on previously treated Candida species. Chemotherapy 2000; 46(4):245-252.
84. Garcia MT, Llorente MT, Minguez F, Prieto J. Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. influence of growth phase. J Infect 2002; 45(4):263-267.
85. Garcia MT, Llorente MT, Minguez F, Prieto J. Post-antifungal effect and effects of sub-MIC concentrations on previously treated Candida spp.: influence of exposure time and concentration. Scand J Infect Dis 2002; 34(3):197-200.
86. Garcia MT, Llorente MT, Lima JE, Minguez F, Del Moral F, Prieto J. Activity of voricona-zole: post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 1999; 31(5):501-504.
87. Vitale RG, Mouton JW, Afeltra J, Meis JF, Verweij PE. Method for measuring postantifungal effect in Aspergillus species. Antimicrob Agents Chemother 2002; 46(6):1960-1965.
88. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocan-dins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53(2):386-389.
89. Chryssanthou E, Sjolin J. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration. J Antimicrob Chemother 2004; 54(5):940-943.
90. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57(1):135-138.
91. Breuker I, Meis JF, Verweij PE, Mouton JW. In vitro activity of the new azole BAL4815 against clinical dermatophyte isolates. In: Microbiology ASf, ed. 45th ICAAC; 2005 October 30-November 2; Washington DC: Database Publishing Group. Inc; 2005:428.
92. Breuker I, Meis JF, Verweij PE, Mouton JW. In vitro activity of the new azole BAL4815 against clinical candida isolates comprising resistant C. albicans and less susceptible candida spp. In: Microbiology ASf, ed. 45th ICAAC; December 16-19; Washington DC: Database Publishing Group. Inc; 2005.
93. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activity of amphotericin B, caspofungin, itraconazole, posaconazole and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M-38 A, Sensititre YeastOne and the E-test 10.1128/AAC.01539-06. Antimicrob Agents Chemother 2006:AAC.01539-06.
94. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12(4):501-517.
95. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 14(6):919-924.
96. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100(6):617-623.
97. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39(1):1-8.
98. Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother 2006; 50(10):3496-3498.
99. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006; 44(suppl):367-371.
100. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44(1):79-86.
101. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 2006; 50(7):2374-2383.
102. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42(5):1105-1109.
103. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47(4):1193-1199.
104. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacody-namics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47(10):3165-3169.
105. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48(1):137-142.
106. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in non-neutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51(1):35-39.
107. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19(2):435-447.
108. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42(7-8):443-451.
109. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44(3):819-826.
110. Mouton JW, Schmitt-Hoffmann A, Punt NC. Monte Carlo Simulations of BAL8557: a New Water-soluble Azole with Antifungal Activity. In: Microbiology ASf, ed. 44th ICAAC; October 30-November 2; Washington DC; 2004:10.
111. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacoki-netic properties and therapeutic use in major superficial and systemic mycoses in immuno-compromised patients. Drugs 1995; 50(4):658-690.